Properties of Pathogen-Inactivated Plasma Components

Transfusion Medicine Reviews

Volumn 23, Issue 2, 2009, Pages 124-133

  Prowse, Christopher ^a  

^a SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FRESH FROZEN PLASMA;

ACUTE LUNG INJURY; ARTICLE; BIOTECHNOLOGY; BLOOD CLOTTING; BLOOD COMPONENT; BLOOD TRANSFUSION; COST EFFECTIVENESS ANALYSIS; HUMAN; MICROBIAL CONTAMINATION; REDUCTION; TOXICOLOGY;

BLOOD TRANSFUSION; BLOOD-BORNE PATHOGENS; DETERGENTS; DISINFECTION; FILTRATION; HUMANS; LIGHT; RADIATION-SENSITIZING AGENTS; STERILIZATION;

EID: 62349127703     PISSN: 08877963     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tmrv.2008.12.004     Document Type: Article

References (67)

1. Webert K.E., Cserti C.M., Hannon J., et al. Proceedings of a Consensus Conference: Pathogen inactivation-making decisions about new technologies. Transfus Med Rev 22 (2008) 1-34
2. Horowitz B., Bonomo R., Prince A.M., et al. Solvent/detergent-treated plasma: A virus-inactivated substitute for fresh frozen plasma. Blood 79 (1992) 826-831
3. Biesert L., and Suhartono H. Solvent/detergent treatment of human plasma-A very robust method for virus inactivation. Validated virus safety of OCTAPLAS. Vox Sang 74 Suppl 1 (1998) 207-212
4. Lambrecht B., Mohr H., Knüver-Hopf J., and Schmitt H. Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light. Vox Sang 60 (1991) 207-213
5. Lin L., Hanson C.V., Alter H.J., et al. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 45 (2005) 580-590
6. Goodrich R.P. The use of riboflavin for the inactivation of pathogens in blood products. Vox Sang 78 Suppl 2 (2000) 211-215
7. Ruane P.H., Edrich R., Gampp D., et al. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 44 (2004) 877-885
8. Burnouf-Radosevich M., Burnouf T., and Huart J.J. A pasteurized therapeutic plasma. Infusionsther Transfusionsmed 19 (1992) 91-94
9. Burnouf T., Radosevich M., El-Ekiaby M., et al. Nanofiltration of single plasma donations: Feasibility study. Vox Sang 84 (2003) 111-119
10. O'Shaugnessy D.F., Atterbury C., Bolton-Maggs P., et al. for the British Committee for Standards in Haematology. Guidelines for the use of fresh frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 126 (2004) 11-28. http://www.bcshguidelines.com/pdf/Amendments_FFP_091205.pdf with December 2005 update: http://www.bcshguidelines.com/pdf/Amendments_FFP_091205.pdf
11. Stanworth S.J., Brunskill S.J., Hyde C.J., et al. Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials. Br J Haematol 126 (2004) 139-152
12. Garwood M., Cardigan R., Drummond O., et al. The effect of methylene blue photoinactivation and methylene blue removal on the quality of fresh-frozen plasma. Transfusion 43 (2003) 1238-1247
13. Osselaer J.C., Debry C., Goffaux M., et al. Coagulation function in fresh-frozen plasma prepared with two photochemical treatment methods: Methylene blue and amotosalen. Transfusion 48 (2008) 108-117
14. Schlenke P., Hervig T., Isola H., et al. Photochemical treatment of plasma with amotosalen and UVA light: Process validation in three European blood centers. Transfusion 48 (2008) 697-705
15. Cardigan R., Prowse C., and Williamson L.M. Processing and components: Leucoreduction and pathogen reduction. In: Barbara J.A.J., Regan F.A.M., and Contreras M.C. (Eds). Transfusion Microbiology (2008), Cambridge University Press 239-258
16. Zeiler T., Wittmann G., Zimmermann R., et al. The effect of virus inactivation on coagulation factors in therapeutic plasma. Br J Haematol 111 (2000) 986-987
17. Doyle S., O'Brien P., Murphy K., et al. Coagulation factor content of solvent/detergent plasma compared with fresh frozen plasma. Blood Coagul Fibrinolysis 14 (2003) 283-287
18. Yarranton H., Lawrie A.S., Purdy G., et al. Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura. Transfus Med 14 (2004) 39-44
19. Hornsey V.S., Drummond O., Morrison A., et al. Pathogen reduction of fresh plasma using riboflavin and UV light: Effects on plasma coagulation proteins. Transfusion (2008) (submitted for publication)
20. Coignard B.P., Colquhoun S.D., Nguyen G.T., et al. Intra-operative deaths in liver transplant recipients associated with the use of solvent/detergent plasma. Hepatology 36 (2002) A209 (abstract)
21. Salge-Bartels U., Breitner-Ruddock S., Hunfeld A., et al. Are quality differences responsible for different adverse reactions reported for SD-plasma from USA and Europe. Transfusion Medicine 16 (2006) 266-275
22. Magner J.J., Crowley K.J., and Boylan J.F. Fatal fibrinolysis during orthotopic liver transplantation in patients receiving solvent/detergent-treated plasma (Octaplas). J Cardiothorac Vasc Anesth 21 (2007) 410-413
23. de la Rubia J., Arriaga F., Linares D., et al. Role of methylene blue-treated fresh frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura. Br J Haematol 114 (2001) 721-723
24. Alvarez-Larren A., Del Rio J., Ramirez C., et al. Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Vox Sang 86 (2004) 246-251
25. Cardigan R., Allford S., and Williamson L.M. Levels of von Willebrand factor cleaving protease are normal in methylene blue treated fresh frozen plasma. Br J Haematol 117 (2002) 253-254
26. Koenigbauer U.F., Eastlund T., and Day J.W. Clinical illness due to parvovirus B19 infection after infusion of solvent/detergent treated pooled plasma. Transfusion 41 (2001) 1203-1206
27. Ciaravino V., McCullough T., and Cimino G. The role of toxicology assessment in transfusion medicine. Transfusion 43 (2003) 1481-1492
28. Pohler P., Leuschner F., Gravemann U., et al. Methylene blue-treated plasma: Toxicological profile of methylene blue and its photoproducts. Poster presented at the 37th Congress of the DGTI, Mannheim, September 21-24 (2004) (abstract)
29. Borgman M.A., Spinella P.C., Perkins J.G., et al. The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. J Trauma 63 (2007) 805-813
30. Hellstern P., Larbig E., Walz G.A., et al. Prospective study on efficacy and tolerability of solvent/detergent-treated plasma in intensive care unit patients. Infusionsther Transfusionsmed 20 suppl 2 (1993) 16-18
31. Inbal A., Epstein O., Blickstein D., et al. Evaluation of solvent/detergent treated plasma in the management of patients with hereditary and acquired coagulation disorders. Blood Coagul Fibrinolysis 4 (1993) 599-604
32. Solheim B.G., Svennevig J.L., Mohr B., et al. The use of Octaplas in patients undergoing open heart surgery. In: Muller-Berghaus G. (Ed). DIC: Pathogenesis, Diagnosis and Therapy of Disseminated Intravascular Fibrin Formation (1993), Elsevier, Amsterdam 253-262
33. Horowitz M.S., and Pehta J.C. SD plasma in TTP and coagulation factor deficiencies for which no concentrates are available. Vox Sang 74 suppl 1 (1998) 231-235
34. Pehta J.C. Clinical studies with solvent detergent-treated products. Transfus Med Rev 10 (1996) 303-311
35. Williamson L.M., Llewelyn C.A., Fisher N.C., et al. A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation. Transfusion 39 (1999) 1227-1234
36. Wieding J.U., Rathgeber J., Zenker D., et al. Prospective randomized and controlled study on solvent/detergent versus methylene blue/light virus-inactivated plasma. Transfusion 39 suppl (1999) 23s (abstract)
37. Beck K.H., Mortelsmans Y., Kretschmer V.V., et al. Comparison of solvent/detergent-inactivated plasma and fresh frozen plasma under routine clinical conditions. Infusionsther Transfusionsmed 27 (2000) 144-148
38. Lerner R.G., Nelson J., Sorcia E., et al. Evaluation of solvent/detergent-treated plasma in patients with a prolonged prothrombin time. Vox Sang 79 (2000) 161-167
39. Haubelt H., Blome M., Kiessling A.H., et al. Effects of solvent/detergent-treated plasma and fresh-frozen plasma on haemostasis and fibrinolysis in complex coagulopathy following open-heart surgery. Vox Sang 82 (2002) 9-14
40. Solheim B.G., Bergan A., Brosstad F., et al. Fibrinolysis during liver transplant and use of solvent/detergent virus-inactivated plasma (ESDEP/Octaplas). Anesth Analg 96 (2003) 1230-1231 author reply 1231-1232 (letter)
41. Solheim B.G. Universal pathogen-reduced plasma in elective open-heart surgery and liver resection. Clin Med Res 4 (2006) 209-217
42. Tollofsrud S., Noddeland H., Svennevig J.L., et al. Universal fresh frozen plasma (Uniplas): A safe product in open-heart surgery. Intensive Care Med 29 (2003) 1736-1743
43. Solheim B.G., Granov D.A., Juravlev V.A., et al. Universal fresh-frozen plasma (Uniplas): An exploratory study in adult patients undergoing elective liver resection. Vox Sang 89 (2005) 19-26
44. Chekrizova V., and Murphy W.G. Solvent-detergent plasma: Use in neonatal patients, in adult and paediatric patients with liver disease and in obstetric and gynaecological emergencies. Transfus Med 16 (2006) 85-91
45. McCarthy L.J. The experience of treating patients with thrombotic thrombocytopenic purpura with solvent detergent plasma. Br J Haematol 133 (2006) 107 author reply 108 (letter)
46. Flamholz R., Jeon H.R., Baron J.M., and Baron B.W. Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent/detergent-treated plasma: Is its decreased protein S activity clinically related to their development of deep venous thromboses. J Clin Apheresis 15 (2000) 169-172
47. Yarranton H., Cohen H., Pavord S.R., et al. Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura. Br J Haematol 121 (2003) 778-785
48. Wieding J.U., and Neumeyer H. Initial experiences with methylene blue virus inactivated fresh frozen plasma: Results of a clinical and in vitro study. Infusionsther Transfusionsmed 19 (1992) 84-90
49. Pohl U., and Mohr H. Virus inactivation of plasma by methylene blue/light exposure: Clinical experience. Transfus Today 2 (1994) 2-3
50. Pohl U., and Beyer H.J. Safety and tolerance of methylene blue virus inactivated fresh frozen plasma: The lower saxony experience. ISBT Regional Conference (Venice) (1995) (abstract)
51. Pohl U., and Wieding J.U. Treatment of patients with severe congenital coagulation factor V or XI deficiency with methylene blue virus inactivated plasma. ISBT Vth Regional (European) congress, Venice (1995) (abstract)
52. Pohl U., and Becker M. Methylene blue virus inactivated fresh frozen plasma in the treatment of patients with thrombotic thrombocytopenic purpura. ISBT Vth Regional (European) congress, Venice (1995) (abstract)
53. Pohl U, Mohr H. Experiences in the Clinical Use of Plasma Photodynamically Virus Inactivated by the Methylene Blue/Light Procedure 24th Congress of the ISBT 1996: Poster 1/2E-41 OP (abstract)
54. Hernandez J.M., Castella D., Claparols M., et al. Clinical use of fresh frozen plasma virus inactivated with methylene blue. Transfusion 39 (1999) 25S (S94P) (abstract)
55. Simonsen A.C., and Sorensen H. Clinical tolerance of methylene blue virus-inactivated plasma: A randomized crossover trial in 12 healthy human volunteers. Vox Sang 77 (1999) 210-217
56. Atance R., Pereira A., and Ramírez B. Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate. Transfusion 41 (2001) 1548-1552
57. Mintz P.D., Neff A., MacKenzie M., Goodnough L.T., et al. A randomized, controlled phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion 46 (2006) 1693-1704
58. Hambleton J., Wages D., Radu-Radulescu L., et al. Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin. Transfusion 42 (2002) 1302-1307
59. Hambleton J., Wages D., Radu-Radulescu L., et al. The Kinetics of Proteins C & S Activity are Retained in Intercept Plasma (IFFP) poster at Paris IST Congress July (2001) (abstract)
60. de Alarcon P., Benjamin R., Dugdale M., et al. Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: Transfusion of patients with congenital coagulation factor deficiencies. Transfusion 45 (2005) 1362-1372
61. Mintz P.D., Bass N.M., Petz L.D., et al. Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease. Blood 107 (2006) 3753-3759
62. Flesland O. A comparison of complication rates based on published haemovigilance data. Intensive Care Med 33 Suppl 1 (2007) S17-S21
63. Renaudier P., Schlanger S., Mai M.P.V., et al., on behalf of the French Hemovigilance Network. Epidemiology of transfusion related acute lung injury in France: Preliminary results. Transfus Med Hemother 35 (2009) 89-91
64. AuBuchon J.P., and Birkmeyer J.D. Safety and cost-effectiveness of solvent-detergent-treated plasma. In search of a zero-risk blood supply. JAMA 272 (1994) 1210-1214
65. Jackson B.R., AuBuchon J.P., and Birkmeyer J.D. Update of cost-effectiveness analysis for solvent-detergent treated plasma. J Am Med Assoc 282 (1999) 329-330
66. Pereira A. Cost-effectiveness of transfusing virus-inactivated plasma instead of standard plasma. Transfusion 39 (1999) 479-487
67. Riedler G.F., Haycox A.R., Duggan A.K., and Dakin H.A. Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma. Vox Sang 85 (2003) 88-95